- Nobel prize a timely reminder, Hiroshima locals say
- Hezbollah fires at Israel as wars rage on Yom Kippur
- Analysts warn more detail needed on new China economic measures
- China tees up fresh spending to boost ailing economy
- China says will issue special bonds to boost ailing economy
- China offers $325 bn in fiscal stimulus for ailing economy
- Dodgers drop Padres 2-0 to advance in MLB playoffs
- Alexei Navalny wrote he knew he would die in prison in new memoir
- Last-minute legal ruling allows betting on US election
- Despite hurricanes, Floridians refuse to leave 'paradise'
- Israel observes Yom Kippur amid firestorm over Lebanon strikes
- Trump demonizes migrants in dark, misleading speech
- X says 'alert' to manipulation efforts after pro-Russia bots report
- US, European markets rise before Boeing unveils sweeping job cuts
- Small Quebec company dominates one part of NHL hockey: jerseys
- Comoros shock Tunisia, Salah, Mbeumo strike in AFCON qualifiers
- Boeing to cut 10% of workforce as it sees big Q3 loss
- Germany win in Nations League as 10-man Dutch rescue point
- Undav brace sends Germany to victory against Bosnia
- Israel says fired at 'threat' near UN position in Lebanon
- Want to film in Paris? No sexism allowed
- Ecuador's last mountain iceman dies at 80
- Milton leaves at least 16 dead, millions without power in Florida
- Senegal set to announce breakaway development agenda: PM
- UN says 2 peacekeepers wounded in south Lebanon explosions
- Injury-hit Australia thrash 'embarrassing' Pakistan at Women's T20 World Cup
- Internal TikTok documents show prioritization of traffic over well-being
- Israel says fired at 'immediate threat' near UN position in Lebanon
- New US coach Pochettino hails Pulisic but worries over workload
- Brazil orders closure of 2,000 betting sites
- UK govt urged to raise pro-democracy tycoon's case with China
- Sculptor Lalanne's animal creations sell for $59 mn
- From Tesla to Trump: Behind Musk's giant leap into politics
- US, European markets rise as investors weigh rates, earnings
- In Colombia, children trade plastic waste for school supplies
- Supercharged hurricanes trigger 'perfect storm' for disinformation
- JPMorgan Chase profits top estimates, bank sees 'resilient' US economy
- Djokovic proves staying power as he progresses to Shanghai semi-finals
- Sheffield Utd boss Wilder 'numb' after Baldock death
- Little progress at key meet ahead of COP29 climate summit
- Fans immerse themselves in Marina Abramovic's first China exhibition
- Israel says conducting review after UN peacekeepers wounded in Lebanon
- 'Party atmosphere': Skygazers treated to another aurora show
- Djokovic 'overwhelmed' after 'greatest rival' Nadal's retirement
- Zelensky in Berlin says hopes war with Russia will end next year
- Kyrgyzstan opens rare probe into glacier destruction
- European Mediterranean states discuss Middle East, migration
- Djokovic proves staying power as progresses to Shanghai semi-finals
- Hurricane Milton leaves at least 16 dead as Florida cleans up
- Britain face 'ultimate challenge' in America's Cup duel with New Zealand
Mailed abortion pills found to be safe ahead of US ruling
Abortions administered as pills sent in the mail are just as safe and effective as those provided in person, a US study said Thursday ahead of a Supreme Court ruling on restricting the medication.
Abortion pills have become the latest battleground in the fight over reproductive rights in the United States after the conservative-dominated Supreme Court overturned the landmark Roe v. Wade ruling in 2022.
The decision led to more than a dozen states banning abortion, while others severely restricted it.
The Supreme Court will hear arguments next month on a bid led by anti-abortion groups to restrict access to mifepristone, one of two pills used in medical abortions.
In 2021, as medical visits became more difficult during the Covid-19 pandemic, the US Food and Drug Administration (FDA) removed the face-to-face requirement for dispensing abortion pills, allowing them to be posted.
The case before the Supreme Court includes a call for this decision to be overturned.
The new study, published in the journal Nature Medicine, looked at data from more than 6,000 abortions using pills supplied by online clinics in 20 states between April 2021 and January 2022.
There were no "serious adverse events" in 99.8 percent of these medical abortions and no follow-up care was needed in 98 percent of cases.
Both figures are similar to those for abortion pills dispensed to patients in person at clinics and doctors' offices.
The study showed the FDA was right to allow abortion pills to be posted, said lead author Ushma Upadhyay, a public health and reproductive social scientist at the University of California, San Francisco.
"Our findings make it abundantly clear that the case at the Supreme Court is simply an attempt to restrict access to abortion care, even in those states where it's legal," she said in a statement.
- 'Essential health service' -
The researchers also compared abortion consultations conducted by video call with those conducted by secure text message, finding that both were equally safe and effective.
These methods allow patients to protect their privacy while making abortion more accessible, they said.
"A ruling against this method and the FDA's rigorous science review process would be a huge blow to the American public and make this essential health service harder to get," Upadhyay said.
The study has already been cited in a brief submitted to the Supreme Court, which has said it will hear oral arguments in the mifepristone case on March 26.
The court is expected to rule by the end of June -- four months before the US presidential election in which abortion is expected to be a major issue.
Medical abortions account for more than half of all pregnancy terminations in the US.
Mifepristone has been found to be safe and effective in hundreds of studies covering dozens of countries.
Last week, a study casting doubt on the drug's safety was retracted by its publisher.
The study, which was repeatedly cited by a federal judge who ruled against mifepristone last year, demonstrated "a lack of scientific rigour that invalidates or renders unreliable the authors' conclusions," publisher Sage said.
D.Kaufman--AMWN